Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Jun. 30, 2016 | Sep. 06, 2016 | |
Document And Entity Information | ||
Entity Registrant Name | SIGNAL BAY, INC. | |
Entity Central Index Key | 715,788 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --09-30 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 780,048,869 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2,016 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jun. 30, 2016 | Sep. 30, 2015 |
Current Assets: | ||
Cash and Cash Equivalents | $ 45,768 | $ 25,966 |
Accounts Receivable | 10,660 | 11,546 |
Prepaid Expense | 4,856 | 5,000 |
Total current assets | 61,284 | 42,512 |
Property, Plant and Equipment | ||
Property, Plant and Equipment | 307,450 | 159,034 |
Accumulated Depreciation | (59,074) | (26,994) |
Property, Plant and Equipment, net | 248,376 | 132,040 |
Other Assets | ||
Cost Basis Investment | 40,000 | 40,000 |
Security Deposit | 6,476 | |
Intangible Assets (net of amortization of $40,543 and $0) | 1,156,463 | 67,428 |
Goodwill | 659,271 | 446,743 |
Total Other Assets | 1,862,210 | 554,171 |
TOTAL ASSETS | 2,171,870 | 728,723 |
Liabilities | ||
Accounts Payable | 135,546 | 46,324 |
Accrued Liabilities | 11,659 | |
Current Portion - Notes Payable - Related Party | 343,007 | 133,507 |
Convertible Loan (net of unamortized discount of $109,571 and $64,062) | 213,249 | 38,438 |
Interest Expense Payable | 8,767 | |
Loans Payable | 64,300 | |
Derivative Liabiity | 376,710 | 200,460 |
Total Current Liabilities | 1,141,579 | 430,388 |
Notes Payable - Related Party, less Current Portion | 880,085 | 13,047 |
Total Liabilities | 2,021,644 | 443,435 |
Stockholders' Equity | ||
Series A Convertible Preferrred Stock, Par Value $.0001, 1,840,000 authorized, 1,840,000 issued and outstanding at June 30, 2016 and September 30, 2015, respectively | 184 | 184 |
Series B Convertible Preferrred Stock, Par Value $.0001, 5,000,000 authorized, 5,000,000 issued and outstanding at June 30, 2016 and September 30, 2015, respectively | 500 | 500 |
Series C Convertible Preferrred Stock, Par Value $.0001, 500,000 authorized, 500,000 and 0 shares issued and outstanding at June 30, 2016 and September 30, 2015, respectively | 50 | |
Common Stock, Par Value $.0001, 750,000,000 authorized, 584,986,814 and 398,648,595 issued and outstanding at June 30, 2016 and September 30, 2015, respectively | 58,499 | 39,865 |
Additional Paid In Capital | 2,214,049 | 1,654,597 |
Accumulated Deficit | (2,322,884) | (1,506,975) |
Total Stockholders' Equity | (49,602) | 188,171 |
Non controlling Interests | 199,808 | 97,117 |
Total Equity | 150,206 | 285,288 |
Total Liabilities and Stockholders' Equity | $ 2,171,870 | $ 728,723 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) | Jun. 30, 2016 | Sep. 30, 2015 |
Consolidated Balance Sheets Parenthetical | ||
Intangible Assets | $ 40,543 | $ 0 |
Convertible Loan | $ (109,571) | $ (64,062) |
Series A Convertible Preferred Stock, Par Value | $ .0001 | $ 0.0001 |
Series A Convertible Preferred Stock, Shares Authorized | 1,840,000 | 1,840,000 |
Series A Convertible Preferred Stock, Shares Issued | 1,840,000 | 1,840,000 |
Series A Convertible Preferred Stock, Shares Outstanding | 1,840,000 | 1,840,000 |
Series B Convertible Preferred Stock, Par Value | $ 0.0001 | $ 0.0001 |
Series B Convertible Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 |
Series B Convertible Preferred Stock, Shares Issued | 5,000,000 | 5,000,000 |
Series B Convertible Preferred Stock, Shares Outstanding | 5,000,000 | 5,000,000 |
Series C Convertible Preferred Stock, Par Value | $ 0.0001 | $ 0.0001 |
Series C Convertible Preferred Stock, Shares Authorized | 500,000 | 500,000 |
Series C Convertible Preferred Stock, Shares Issued | 500,000 | 0 |
Series C Convertible Preferred Stock, Shares Outstanding | 500,000 | 0 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 750,000,000 | 750,000,000 |
Common stock, shares issued | 584,986,814 | 398,648,595 |
Common stock, shares outstanding | 584,986,814 | 398,648,595 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Revenues | ||||
Testing Services | $ 83,709 | $ 163,366 | ||
Consulting Services | 32,939 | 6,399 | 228,612 | 16,812 |
Total Revenue | 116,648 | 6,399 | 391,978 | 16,812 |
Operating Expenses | ||||
Selling, general and administrative expenses | 242,438 | 320,939 | 727,675 | 1,126,426 |
Depreciation and Amortization | 46,981 | 5,612 | 71,142 | 10,680 |
Total Operating Expense | 289,419 | 326,551 | 798,816 | 1,137,106 |
Loss from Operations | (172,771) | (320,152) | (406,838) | (1,120,294) |
Other expense | ||||
Interest expense | 44,397 | 185,372 | ||
Loss on disposal of assets | 720 | |||
Loss on derivatives | 203,696 | 238,038 | ||
Total other expense | 248,093 | 424,130 | ||
Net Loss | (420,864) | (320,152) | (830,968) | (1,120,294) |
Less: Loss attributable to non-controlling interests | (5,321) | (15,059) | ||
Net Loss attributable to Signal Bay, Inc. | $ (415,543) | $ (320,152) | $ (815,909) | $ (1,120,294) |
Basic and Diluted Net Loss Per Share | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted Average Share Outstanding Basic and Diluted | 513,768,896 | 353,102,137 | 440,380,497 | 323,902,484 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
Cash flows from operating activities | ||
Net loss | $ (830,968) | $ (1,120,294) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Loss on disposal of asset | 720 | |
Loss on conversion of debt | 90,000 | |
Default penalty on convertible debenture | 51,229 | |
Stock based compensation | 92,991 | 907,880 |
Depreciation and amortization expense | 71,142 | 10,680 |
Amortization of debt discount | 90,291 | |
Derivative expense | 238,038 | |
Changes in operating assets and liabilities: | ||
Accounts receivable | 886 | (4,900) |
Prepaid expenses and other current assets | 144 | |
Security deposits | (6,476) | |
Accounts payable | 132,055 | 5,086 |
Accrued liabilities | (11,659) | |
Interest payable | 11,775 | |
Net cash used in operating activities | (159,832) | (111,548) |
Cash flows from investing activities | ||
Net cash paid in acquisition of subsidiary | 9,055 | |
Hardware and equipment purchased | (11,699) | (2,194) |
Domain, website and customer list acquisition | (3,500) | |
Furniture and fixtures | (10,413) | |
Net cash used in investing activities | (2,644) | (16,107) |
Cash flows from financing activities | ||
Proceeds from issuance of common stock | 79,500 | |
Proceeds from convertible notes, net of original issue discounts and fees | 193,640 | |
Proceeds from loan payable | 43,836 | |
Payment on loan payable | (7,036) | |
Proceeds from notes payable - related party | 20,500 | |
Payments on notes payable - related party | (68,662) | |
Proceeds from related party advances | 52,500 | |
Net cash provided by financing activities | 182,278 | 132,000 |
Net cash increase for period | 19,802 | 4,345 |
Cash balance, beginning of period | 25,966 | |
Cash balance, end of period | 45,768 | 4,345 |
Cash paid for: | ||
Interest | 12,098 | |
Income Taxes | ||
Noncash investing and financing activities: | ||
Software purchased with common stock | 58,333 | |
Domain, websites, and social media accounts purchased with common stock | 31,250 | |
4% Interest in Libra Wellness Center, LLC for Installment Note to related party | 40,000 | |
Converted $40K liability to non-affiliated consultant for 12,000,000 shares | 40,000 | |
Debt discount from derivative liability | 120,000 | |
Conversion of Convertible note and accrued interest into Common Stock | 88,357 | |
Reclassification of derivative liability to APIC | 181,788 | |
Acquisition of Oregon Analytical Services' assets through issuance of preferred shares, common shares and note payable | 852,500 | |
Acquisition of Smith Scientific through issuance of preferred shares, common shares and note payable | 471,000 | |
Expenses paid by note payable | $ 45,000 |
NATURE OF ACTIVITIES AND CONTIN
NATURE OF ACTIVITIES AND CONTINUANCE OF BUSINESS | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 1 - NATURE OF ACTIVITIES AND CONTINUANCE OF BUSINESS | Signal Bay, Inc., a Colorado corporation and its subsidiaries provide advisory, management and analytical testing services to the emerging legalized cannabis industry. Signal Bay, Inc. was originally incorporated in the State of New York, December 12, 1977 under the name 3171 Holding Corporation. On February 22, 1979 the name was changed to Electronomic Industries Corp. and on February 23, 1983 the name was changed to Quantech Electronics Corp. The Company was reincorporated in the State of Colorado on December 15, 2003. On August 29, 2014, the Company completed a reverse merger with Signal Bay Research, Inc., a Nevada Corporation, and took over its operations. In September 2014, the Company changed its name from Quantech Electronics Corp. to Signal Bay, Inc. The Company has selected September 30 as its fiscal year end. Signal Bay, Inc. is domiciled in the State of Colorado, and its corporate headquarters are located in Bend, Oregon. As a part of and prior to the consummation of the reverse merger, William Waldrop and Lori Glauser, principals of Signal Bay Research, Inc., purchased 28,811,933 shares of the Company (80% of the issued and outstanding common stock) from WB Partners. The merger between the Company and Signal Bay Research was finalized and closed contemporaneously with the share purchase. As part of this share purchase, Mr. Waldrop and Ms. Glauser became the officers and directors of the Company. Signal Bay Research was acquired through the issuance of 254,188,067 shares of common stock and 5,000,000 shares of Series B Preferred Stock to Mr. Waldrop and Ms. Glauser, pro rata. After the reverse merger, William Waldrop and Lori Glauser individually each own 127,500,000 shares of common stock and 2,500,000 shares of Series B Preferred stock in the Company. Immediately prior to the reverse merger, neither William Waldrop nor Lori Glauser had any interest in the Company. Immediately after to the reverse, WB Partners owned less than 5% of the common stock. The company filed a Form 10-12G on November 25, 2014, and was determined to be a shell company by the SEC as per the Form 10-12G/A which went effective on January 24, 2015. As of January 29, 2015, the company filed an 8-K stating it entered into a material agreement and was no longer a shell company. After the reverse merger, Signal Bay Research, Inc. continues to operate as a wholly owned subsidiary providing the licensing, compliance, research and advisory services for Signal Bay, Inc. Signal Bay Services was formed on January 25, 2015, as the management services division of Signal Bay. Currently, Signal Bay Services has one contract with Libra Wellness Services, LLC with anticipated engagement commencing in January 2017. On September 17, 2015, Signal Bay entered into a share exchange agreement with CR Labs, Inc., an Oregon Corporation, pursuant to which the company issued 40,000,000 shares of the Companys common stock resulting in exchange for 80% of the outstanding common stock of CR Labs, Inc. EVIO Inc. was formed on April 04, 2016 to become the holding company for all laboratory operations. EVIO Labs Eugene was formed on May 23, 2016, as a wholly owned subsidiary of EVIO Inc. Subsequently on May 24, 2016, EVIO Labs Eugene acquired all of the assets of Oregon Analytical Services, LLC, inclusive of client lists, equipment, trade names, and personnel. On June 1, 2016, EVIO Inc. entered into a share purchase agreement to purchase 80% of the outstanding common stock of Smith Scientific Industries, Inc. d/b/a Kenevir Research in Medford, OR. Going Concern The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has negative working capital, recurring losses, and does not have an established source of revenues sufficient to cover its operating costs. These factors raise substantial doubt about the Companys ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations. The accompanying financial statements do not include any adjustments that may be necessary if the Company is unable to continue as a going concern. In the coming year, the Companys foreseeable cash requirements will relate to continual development of the operations of its business, maintaining its good standing and making the requisite filings with the Securities and Exchange Commission, and the payment of expenses associated with operations and business developments. The Company may experience a cash shortfall and be required to raise additional capital. Historically, it has mostly relied upon internally generated funds such as shareholder loans and advances to finance its operations and growth. Management may raise additional capital by retaining net earnings or through future public or private offerings of the Companys stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing. The Companys failure to do so could have a material and adverse effect upon it and its shareholders. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Basis of Presentation: The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Companys most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited consolidated financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted Principles of Consolidation: The Company prepares its financial statements on the accrual basis of accounting. The accompanying consolidated financial statements include the accounts of the Company and its wholly and partially owned subsidiaries, all of which have a fiscal year end of September 30. All significant intercompany accounts, balances and transactions have been eliminated in the consolidation. The Company consolidates its subsidiaries in accordance with ASC 810, and specifically ASC 810-10-15-8 which states, the usual condition for a controlling financial interest is ownership of a majority voting interest, and, therefore, as a general rule ownership by one reporting entity, directly or indirectly, or over 50% of the outstanding voting shares of another entity is a condition pointing toward consolidation. Use of Estimates The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements estimates or assumptions could have a material impact on Signal Bay, Inc. financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Signal Bay, Inc. financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented. Financial Instruments Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company's financial instruments consist principally of cash, accounts payable, and accrued liabilities. Pursuant to ASC 820 and 825, the fair value of cash is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. The following table sets forth by level with the fair value hierarchy the Company's financial assets and liabilities measured at fair value on June 30, 2016: Level 1 Level 2 Level 3 Total Liabilities Derivative financial instruments $ - $ - $ 376,710 $ 376,710 Recently Issued Accounting Pronouncements Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company. |
ACQUISITIONS
ACQUISITIONS | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 3 - ACQUISITIONS | CR Labs, Inc., On September 17, 2015 the Company performed a share exchange for 80% ownership of CR Labs, Inc., from its founders. CR Labs is an Oregon company engaged in providing analytical testing services for the medical marijuana industry in compliance with the Oregon Health Authority. The costs related to the transaction were $42,193 and were expensed during 2015. The Company applied the acquisition method to the business combination and valued each of the assets acquired (cash, accounts receivable, and property, plant and equipment) and liabilities assumed (accounts payable) at fair value as of the acquisition date. The cash, accounts receivable and accounts payable were deemed to be recorded at fair value as of the acquisition date. The Company determined the fair value of property, plant and equipment to be historical book value. The preliminary allocation of the purchase price was based on estimates of the fair value of the assets and liabilities assumed. Under the purchase agreement, the Company issued 40,000,000 shares of common stock. These shares had an acquisition date fair value of $400,000. The following table shows the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: ASSETS ACQUIRED: CASH $ 2,970 ACCOUNT RECEIVABLE 3,550 PROPERTY PLANT AND EQUIPMENT 43,360 CUSTOMER LIST 67,428 GOODWILL 446,743 TOTAL ASSETS ACQUIRED 564,051 LESS LIABILITIES ASSUMED ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (36,421 ) NOTES PAYABLE (27,630 ) TOTAL LIABILITIES ASSUMED (64,051 ) LESS NONCONTROLLING INTEREST (100,000 ) NET ASSETS ACQUIRED FROM CR LABS ACQUISITION $ 400,000 Oregon Analytical Services, LLC On May 24, 2016 the Company through its subsidiary EVIO Inc., executed an asset purchase agreement to acquire 100% of the assets of Oregon Analytical Services, LLC. from its founder. Oregon Analytical Services, LLC was an Oregon company engaged in providing analytical testing services for the medical marijuana industry in compliance with the Oregon Health Authority. The costs related to the transaction were $2,780 and were expensed during 2016. The Company applied the acquisition method as a business combination and valued each of the assets acquired and liabilities assumed at fair value as of the acquisition date. The notes payable was deemed to be recorded at fair value as of the acquisition date. The Company determined the fair value of property, plant and equipment to be market value. The preliminary allocation of the purchase price was based on estimates of the fair value of the assets and liabilities assumed. Under the purchase agreement, the Company issued a promissory note in the amount of $700,000 which is due and payable by May 23, 2010, the company is required to make annual payments of $100,000 if the minimum trailing revenue for EVIO Labs Eugene exceeds $700,000 annually during the term of the promissory note, the Company issued another promissory note in the amount of $72,500 in connection with the acquisition, and 200,000 shares of Preferred Series C Stock. These shares had an acquisition date fair value of $80,000. The following table shows the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Oregon Analytical Services PPA ASSETS ACQUIRED: PROPERTY PLANT AND EQUIPMENT $ 123,143 CUSTOMER LIST 696,153 GOODWILL 60,704 TOTAL ASSETS ACQUIRED 880,000 LESS LIABILITIES ASSUMED NOTES PAYABLE (27,500 ) TOTAL LIABILITIES ASSUMED (27,500 ) NET ASSETS ACQUIRED FROM OREGON ANALYTICAL SERVICES $ 852,500 Smith Scientific Industries, Inc. On June 1, 2016 the Company through its subsidiary EVIO Inc. executed a share purchase agreement for 80% ownership of Smith Scientific Industries, Inc. d/b/a Kenevir Research., from a related party, Anthony Smith, Company Director. Smith Scientific Industries is an Oregon company engaged in providing analytical testing services for the medical marijuana industry in compliance with the Oregon Health Authority. The costs related to the transaction were $2,780 and were expensed during 2016. The Company applied the acquisition method to the business combination and valued each of the assets acquired and liabilities assumed at fair value as of the acquisition date. The cash and accounts payable were deemed to be recorded at fair value as of the acquisition date. The Company determined the fair value of property, plant and equipment to be historical book value. The preliminary allocation of the purchase price was based on estimates of the fair value of the assets and liabilities assumed. Under the purchase agreement, the Company issued a promissory note for $336,000, with required $25,000 to be paid at closing, $75,000 to be paid in two installments within 180 days, and the remaining balance in three annual installments of $58,475, and 300,000 shares of Preferred Series C Stock. These shares had an acquisition date fair value of $135,000. The following table shows the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Smith Scientific Industries ("SSI") PPA ASSETS ACQUIRED: CASH $ 9,055 PROPERTY PLANT AND EQUIPMENT 11,076 CUSTOMER LIST 433,425 GOODWILL 151,824 TOTAL ASSETS ACQUIRED 605,380 LESS LIABILITIES ASSUMED ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (430 ) NOTES PAYABLE (16,200 ) TOTAL LIABILITIES ASSUMED (16,630 ) LESS NONCONTROLLING INTEREST (117,750 ) NET ASSETS ACQUIRED FROM SSI ACQUISITION $ 471,000 In accordance with ASC 805-10-50, the Company is providing the following unaudited pro-forma to present a summary of the combined results of the Companys consolidated operations with all acquisitions. as if the acquisitions had been completed as of the beginning of the reporting period. Adjustments were made to eliminate any inter-company transactions in the periods presented. SIGNAL BAY, INC. AND SUBSIDIARIES STATEMENTS OF CONSOLIDATED OPERATIONS (Unaudited) Nine months ended June 30, 2016 June 30, 2015 (Pro Forma) (Pro Forma) Revenues Testing Services $ 470,504 $ 253,948 Consulting Services 228,612 16,812 Total Revenue 699,116 270,760 Selling, general and administrative expenses 1,048,722 1,195,942 Depreciation and Amortization 72,717 106,951 Operating Expenses 1,121,439 1,302,893 Loss from Operations (422,323 ) (1,032,133 ) Other expense Other (income) expense - (11,036 ) Interest expense 185,363 185,372 Loss on disposal of assets 720 720 Loss on derivatives 238,038 238,038 Other (income) expense 424,121 413,094 Net Loss $ (846,444 ) $ (1,445,227 ) Future Amortization The future amortization associated with the intangible assets acquired in the above mentioned acquisitions is as follows: For the years ended September 30, Amortization 2017 $ 239,401 2018 239,401 2019 239,401 2020 239,401 2021 146,232 Thereafter - Total $ 1,103,836 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 4 - RELATED PARTY TRANSACTIONS | During the nine months ended June 30, 2016, the Company borrowed $20,500 and paid $8,795 from Lori Glauser, our COO, for working capital. The total amount owed is $91,705 and $80,000 as of June 30, 2016 and September 30, 2015, respectively, and are included in the accompanying consolidated balance sheets as current portion of notes payable to related party. The loan is at 0% interest and is to be repaid by September 30, 2016. During the nine months ended June 30, 2016, $48,006 was paid to Newport Commercials Advisors (NCA) for management consulting services, a company which is owned 100% by William Waldrop, our CEO. On June 22, 2015, the Company purchased a 4% ownership of Libra Wellness Center, LLC from Lori J Glauser, our COO for $40,000. The $40,000 is to be paid in one installment due no later than September 30, 2016. The total amount owed is $40,000 as of June 30, 2016 and September 30, 2015 and are included in the accompanying consolidated balance sheets as current portion of notes payable to related party. This transaction has been recorded as a cost basis investment since neither Signal Bay, William Waldrop or Lori Glauser has any additional ownership and do not have any control over Libra Wellness Center, LLC. Libra Wellness Center, LLC has subsequently obtained additional financing resulting in our ownership being diluted to 1.5%. During the nine months ended June 30, 2016, the Company repaid to Eric Ezrine, CR Labs, Shareholder, $9,951. The total amount owed is $16,603 and $26,554 as of June 30, 2016 and September 30, 2015, respectively. As of June 30, 2016, $14,043 and $2,560 are included in the accompanying consolidated balance sheets as current and long-term portions of notes payable to related party, respectively. As of September 30, 2015, $13,047 and $13,507 is included in the accompanying consolidated balance sheets as current and long-term portions of notes payable to related party, respectively. Through March 31, 2016, our executive, administrative and operating offices are located at 2996 Panorama Ridge Dr. Henderson, NV 89052. The office space is being provided by one of our Directors. On May 24, 2016, the company executed an asset purchase agreement with Sara Lausmann, managing member owner of Oregon Analytical Services, LLC, for $972,500. The terms of the purchase required the issuance of 200,000 shares of Series C Preferred Stock, valued at $80,000. $72,500 in a short-term loan and $700,000 in a long-term note. During the nine months ended June 30, 2016, the Company repaid to Sara Lausmann, Vice President Client Services, $24,916. The total amount owed is $747,584 and $0 as of June 30, 2016 and September 30, 2015, respectively. As of June 30, 2016, $47,584 and $700,000 are included in the accompanying consolidated balance sheets as current and long-term portions of notes payable to related party, respectively. On June 1, 2016, the company executed a share purchase agreement with Anthony Smith, for the purchase of 80% of Smith Scientific Industries. for $636,000. The terms of the purchase required the issuance of 300,000 shares of Series C Preferred Stock, valued at $135,000. $336,000 in a promissory note. During the nine months ended June 30, 2016, the Company paid to Anthony Smith, our Chief Science Officer, $25,000. The total amount owed is $311,000 and $0 as of June 30, 2016 and September 30, 2015, respectively. As of June 30, 2016, $133,475 and $177,525 are included in the accompanying consolidated balance sheets as current and long-term portions of notes payable to related party, respectively. |
EQUITY TRANSACTIONS
EQUITY TRANSACTIONS | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 5 - EQUITY TRANSACTIONS | Preferred Stock Designation Series A Convertible Preferred Stock The Company designated 1,850,000 shares of Series A Convertible Preferred Stock (Series A Preferred Stock) with a par value of $0.0001 per share. Dividends: Initially, there will be no dividends due or payable on the Series A Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporations Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed. All shares of the Series A Preferred Stock shall rank (i) senior to the Corporations Common Stock and any other class or series of capital stock of the Corporation hereafter created, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series A Preferred Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series A Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary. The Series A Preferred shall have no liquidation preference over any other class of stock. Except as otherwise required by law, holders of Series A Preferred Stock shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock or any other class or series of preferred stock) for the taking of any corporate action. Conversion at the Option of the Holder. From 12 months from the date of issuance, each holder of shares of Series A Preferred Stock may, at any time and from time to time, convert (an Optional Conversion) each of its shares of Series A Preferred Stock into fully paid and nonassessable shares of Common Stock at a rate equal to 4.9% of the Common Stock. AntiDilution. For a period of 18 months after the Preferred is convertible, the conversion price of the Series A Preferred will be subject to adjustment to prevent dilution in the event that the Company issues additional shares at a purchase price less than the applicable conversion price. The conversion price will be subject to adjustment on a weighted basis that takes into account issuances of additional shares. At the expiration of the antidilution period, the conversion rate in Section VI (A) above shall be equal to a conversion rate equal to 4.9% on the Common Stock. For example, if on the date of expiration of the antidilution clause there are 500,000,000 shares of Common Stock issued and outstanding then each Series A Preferred Stock shall convert at a rate of 13.24 common shares for each 1 Series Preferred Share. The company has evaluated the Series A Preferred Stock in accordance with ASC 815 and has determined their conversion options were for equity and ASC 815 does not apply. The company has evaluated the Series A Preferred Stock in accordance with FASB ASC Subtopic 470-20, and has determined that there is no beneficial conversion feature that must be accounted. The Company has 1,840,000 shares of Series A Convertible Stock issued and outstanding as of June 30, 2016 and September 30, 2015. Series B Convertible Preferred Stock The Company designated 5,000,000 shares of Series B Convertible Preferred Stock (Series B Preferred Stock) with a par value of $0.0001 per share. Initially, there will be no dividends due or payable on the Series B Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporations Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed. All shares of the Series B Preferred Stock shall rank (i) senior to the Corporations Common Stock and any other class or series of capital stock of the Corporation hereafter created, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series B Preferred Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series B Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary. The Series B Preferred shall have no liquidation preference over any other class of stock. Each holder of outstanding shares of Series B Preferred Stock shall be entitled to the number of votes equal to one hundred (100) Common Shares. Except as provided by law, or by the provisions establishing any other series of Preferred Stock, holders of Series B Preferred Stock and of any other outstanding series of Preferred Stock shall vote together with the holders of Common Stock as a single class. Each holder of shares of Series B Preferred Stock may, at any time and from time to time, convert (an Optional Conversion) each of its shares of Series B Preferred Stock into a 100 of fully paid and nonassessable shares of Common Stock; provided, however, that any Optional Conversion must involve the issuance of at least 100 shares of Common Stock. In the event of a reverse split the conversion ratio shall not change. However, in the event a forward split shall occur then the conversion ratio shall be modified to be increased by the same ratio as the forward split. The company has evaluated the Series B Preferred Stock in accordance with ASC 815 and has determined their conversion options were for equity and ASC 815 does not apply. The company has evaluated the Series B Preferred Stock in accordance with FASB ASC Subtopic 470-20, and has determined that there is no beneficial conversion feature that must be accounted. The Company has 5,000,000 shares of Series B Convertible Stock issued and outstanding as of June 30, 2016 and September 30, 2015. Series C Convertible Preferred Stock The Company designated 500,000 shares of Series C Convertible Preferred Stock (Series C Preferred Stock) with a par value of $0.0001 per share. Initially, there will be no dividends due or payable on the Series C Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporations Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed. All shares of the Series C Preferred Stock shall rank (i) senior to the Corporations Common Stock and any other class or series of capital stock of the Corporation hereafter created, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series B Preferred Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series B Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary. Each holder of outstanding shares of Series C Preferred Stock shall be entitled to the number of votes equal to one hundred (500) Common Shares. Except as provided by law, or by the provisions establishing any other series of Preferred Stock, holders of Series B Preferred Stock and of any other outstanding series of Preferred Stock shall vote together with the holders of Common Stock as a single class. Each holder of shares of Series C Preferred Stock may, at any time and from time to time, convert (an Optional Conversion) each of its shares of Series C Preferred Stock into a 500 of fully paid and nonassessable shares of Common Stock; provided, however, that any Optional Conversion must involve the issuance of at least 10,000 shares of Common Stock. In the event of a reverse split the conversion ratio shall not change. However, in the event a forward split shall occur then the conversion ratio shall be modified to be increased by the same ratio as the forward split. The company has evaluated the Series C Preferred Stock in accordance with ASC 815 and has determined their conversion options were for equity and ASC 815 does not apply. The company has evaluated the Series C Preferred Stock in accordance with FASB ASC Subtopic 470-20, and has determined that there is no beneficial conversion feature that must be accounted. During the nine months ended June 30, 2016, the Company issued 300,000 shares of Series C Preferred Stock for the acquisition of Smith Scientific Industries, Inc. and 200,000 shares of Series C Preferred Stock for the acquisition of the assets of Oregon Analytical Services. The Company has 500,000 shares of Series C Convertible Stock issued and outstanding as of June 30, 2016. Common Stock During the nine months ended June 30, 2016, the Company issued the following shares of common stock: · 5,506,250 shares of common stock were issued under the Companys Equity Incentive Plan for 2015, valued at $38,141. The Company recognizes compensation expense ratably over the vesting period. · 18,585,469 shares of common stock were issued to advisors for consulting services valued at $54,850. · 162,246,500 shares of common stock issued for the conversion of convertible debt valued at $88,356. The Company recorded $181,788 to additional paid in capital for the reclassification of derivative liabilities due to conversion of convertible notes. As of June 30, 2016 and September 30, 2015, the Company had 584,986,814 and 398,648,595 shares of common stock issued and outstanding, respectively. |
LOANS PAYABLE
LOANS PAYABLE | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 6 - LOANS PAYABLE | The Company had the following loans payable outstanding as of June 30, 2016 and September 30, 2015: June 30, 2016 September 30, 2015 On April 20, 2016, the Company entered into a Purchase and Sale of Future Receivables agreement (the Agreement) with 1 Global Capital, LLC (1GC) for $40,000. The Agreement calls for 140 daily payments of $400, due on business days, for total payments of $56,000. The Company recognized an original debt discount of $16,000 as interest expense. $ 36,800 $ - On May 24, 2016, the Company assumed a $27,500 Promissory note with annual interest of 25%, as part of the acquisition of Oregon Analytical Services (see note 3). The note is due on demand and requires quarterly payments. 27,500 - 64,300 - Less: current portion of loans payable 64,300 - Long-term portion of loans payable $ - $ - As of June 30, 2016 and 2015, the Company accrued interest of $697 and $0, respectively. During the periods ended June 30, 2016 and 2015, the Company recorded interest expense of $16,697 and $0, respectively. |
CONVERTIBLE DEBT
CONVERTIBLE DEBT | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 7 - CONVERTIBLE DEBT | The Company had the following convertible notes payable outstanding as of June 30, 2016 and September 30, 2015: June 30, 2016 September 30, 2015 St. George Investments, LLC. $ - $ 102,500 Adar Bays, LLC 25,000 - Tangiers Global, LLC - note 1 72,020 - Tangiers Global, LLC note 2 27,500 - Tangiers Global, LLC note 3 76,650 - LG Capital Funding, LLC 76,650 - T McNeil Advisors, LLC 45,000 - Total convertible notes payable 322,820 102,500 Less: debt discount and financing fees (109,571 ) (64,062 ) 213,249 38,438 Less: current portion of convertible notes payable 213,249 38,438 Long-term portion of convertible notes payable $ - $ - The Company recognized amortization expense related to the debt discount and deferred financing fees of $90,291 and $0 for the nine months ended June 30, 2016 and 2015, respectively, which are included in interest expense in the consolidated statements of operations. Debt Issued in fiscal year 2015 On July 23, 2015, Signal Bay, Inc. (the "Company") executed a convertible promissory note with a principal amount of $102,500 (the "Note") to St. George Investments, LLC. ("Lender"). The Note was funded on July 23, 2015 (Purchase Date). The Company may repay this note at any time. This note shall be deemed paid in full if Company pays to Lender (a) the sum of $91,250 (meaning Borrower would receive a $11,250 discount) on or before the date that is ninety (90) days from the Purchase Price Date, or (b) the sum of $97,500 (meaning Borrower would receive a $5,000 discount) on any date after the date that is ninety (90) days from the Purchase Price Date but on or before the date that is one hundred thirty-five (135) days from the Purchase Price Date (the "Prepayment Opportunity Date"). If Borrower does not repay the entire Outstanding Balance of this Note on or before the Prepayment Opportunity Date, it shall receive no prepayment discount and must pay the entire Outstanding Balance of this Note in full on or before the Maturity Date. Lender has the right at any time following an Event of Default, at its election, to convert (each instance of conversion is referred to herein as a "Conversion") all or any part of the Outstanding Balance into shares ("Conversion Shares") of fully paid and non-assessable common stock, $0.0001 par value per share ("Common Stock"), of Borrower as per the following conversion formula: the number of Conversion Shares equals the amount being converted (the "Conversion Amount") divided by the Conversion Price. The conversion price (the "Conversion Price") for each Conversion (as defined below) shall be equal to the product of 70% (the "Conversion Factor") multiplied by the average of the three (3) lowest Closing Bid Prices in the twenty (20) Trading Days immediately preceding the applicable Conversion. On March 31, 2016, Tangiers Global LLC Purchased $115,019 of the note from St. George Investments, resulting in a balance of $25,071 owing to St. George Investments. During the nine months ended June 30, 2016, principal and interest of $85,348 and $3,008, respectively, was converted into 162,246,500 shares of common stock. The corresponding derivative liability as the date of conversion of $181,788 was credited to additional paid in capital. Debt Issued in fiscal year 2016 During the nine months ended June 30, 2016, the Company issued a total of $250,800 notes with the following terms: · Terms 12 months · Annual interest rates ranging from 8% to 10% · Convertible at the option of the holders either at issuance or 6 months from issuance. · Conversion prices are typically based on the discounted (50% - 72% discount) lowest trading prices of the Companys shares during various periods prior to conversion. Certain notes allow the Company to redeem the notes at rates ranging from 100% to 150% depending on the redemption date provided that no redemption is allowed after the 180 th The Company determined that the conversion feature met the definition of a liability in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity's Own Stock and therefore bifurcated the embedded conversion option once the note becomes convertible and accounted for it as a derivative liability. The fair value of the conversion feature was recorded as a debt discount and amortized to interest expense over the term of the note. The Company valued the conversion feature using the Black Scholes valuation model. The fair value of the derivative liability for all the notes that became convertible during the nine months ended June 30, 2016 amounted to $376,710. $235,019 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $170,637 was recognized as a day 1 derivative loss. The following notes were convertible during the nine months ended June 30, 2016: · Adar Bays, LLC · Tangiers Global, LLC 1 · Tangiers Global, LLC 2 · Tangiers Global, LLC 3 |
DERIVATIVE LIABILITY
DERIVATIVE LIABILITY | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 8 - DERIVATIVE LIABILITY | The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, The following table summarizes the derivative liability activity from September 30, 2015 through June 30, 2016. Derivative liabilities Balance - September 30, 2015 $ 200,460 Addition of new derivative 120,000 Day one loss due to derivative 170,637 Loss on change in fair value of the derivative 67,401 Settled upon conversion of debt (181,788 ) Balance - June 30, 2016 $ 376,710 The following table summarizes the loss on derivative liability included in the income statement for the financial periods ended June 30, 2016 and 2015, respectively. Nine Months Ended June 30, 2016 2015 Day one loss due to derivatives on convertible debt $ 170,637 $ - Loss on change in fair value of the derivative 67,401 - Derivative expense $ 238,038 $ - The table below shows the Black-Scholes option-pricing model inputs used by the Company to value the derivative liability, as well as the determined value of the option liability at each measurement date: 6/30/2016 Assumptions Convertible Debt Dividend yield 0.00 % Market price $ 0.0007 Risk-free rate for term 0.21% - 0.59 % Volatility 251.92% - 323.98 % Remaining life (in years) 0.24 - 1.00 |
INDUSTRY SEGMENTS
INDUSTRY SEGMENTS | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 9 - INDUSTRY SEGMENTS | This summary reflects the Company's current segments, as described below. Corporate The parent company provides overall management and corporate reporting functions for the entire organization. Consulting The company provides advisory, licensing and compliance services to the cannabis industry under its brand Signal Bay Research. Consulting clients are located in states that have state managed medical and/or recreational programs. Signal Bay Research assists these companies with license applications, business planning, state compliance and ongoing operational support. Testing Services The company provides analytical testing services to the cannabis industry under the EVIO Labs brand. As of June 30, 2016, EVIO Labs has three operating labs, CR Labs, Inc. d/b/a EVIO Labs, Bend, EVIO Labs Eugene d/b/a Oregon Analytical Services and Smith Scientific Industries d/b/a Kenevir Research. EVIO Labs clients are located in Oregon and consist of growers, processors and dispensaries. Operating under the rules of the Oregon Health Authority, EVIO Labs certifies products have been tested and are free from pesticides and other containments before resale to patients and consumer in the State of Oregon. Nine Months Ended June 30, 2016 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 228,612 $ 163,366 $ 391,978 Segment loss from operations (173,229 ) (112,917 ) (120,692 ) (406,838 ) Total assets 18,545 116,504 2,036,821 2,171,870 Capital expenditures - - 12,407 12,407 Depreciation and amortization - 17,766 53,375 71,141 Nine Months Ended June 30, 2015 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 16,812 $ - $ 16,812 Segment loss from operations (338,509 ) (781,785 ) - (1,120,294 ) Total assets 4,345 139,910 - 144,255 Capital expenditures - 5,694 - 5,694 Depreciation - 10,680 - 10,680 Three Months Ended June 30, 2016 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 32,939 $ 83,709 $ 116,648 Segment income (loss) from operations (34,716 ) (78,980 ) (59,075 ) (172,771 ) Total assets 18,545 116,504 2,036,821 2,171,870 Capital expenditures - - 726 726 Depreciation - (820 ) 47,801 46,981 Three Months Ended June 30, 2015 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 6,399 $ - $ 6,399 Segment loss from operations (22,681 ) (297,471 ) - (320,152 ) Total assets 4,345 139,910 - 144,255 Capital expenditures - 5,694 - 5,694 Depreciation - 5,612 - 5,612 |
COMMITMENTS
COMMITMENTS | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 10 - COMMITMENTS | On November 1, 2015, Signal Bay, Inc. majority owned subsidiary CR Labs, Inc. executed a facility lease for a new building in Bend, OR to provide sufficient space for additional analytical equipment. This lease was guaranteed by the Signal Bay, Inc. to entice the landlord to enter the agreement. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
NOTE 11 - SUBSEQUENT EVENTS | Subsequent to June 30, 2016, the Company issued 177,507,121 shares of common stock for conversion of convertible notes with principal and accrued interest of $34,736. On July 1, 2016, we issued 193,750 shares that vested to members of our advisory committee under the Companys 2015 Equity Incentive Plan, that were valued at $116. On July 12, 2016, we issued 15,000,000 shares of common stock to a consultant for advisory services, that were valued at $7,500 On August 1, 2016, we issued 193,750 shares that vested to members of our advisory committee under the Companys 2015 Equity Incentive Plan that were valued at $504 On August 12, 2016, we issued 1,973,684 shares of common stock to a consultant for advisory services, that were valued at $7,500. On August 15, 2016, the Company amended and restated the Companys 2015 Equity Incentive Plan (the Stock Plan). The amendments to the Stock Plan, among other things, (i) increase the total number of shares of Common Stock which may be subject to awardsissued under the Stock Plan from 60,000,000 to 100,000,000, and (ii) generally update and clarify the terms of the Stock Plan. On August 15, 2016, the Company approved the issuance of 16,000,000 Incentive Stock Options with fifty percent (50%) of the Shares vesting on the first anniversary and the remaining fifty percent (50%) vesting agreement on the second anniversary. On August 15, 2016, the Company approved the issuance of 15,500,000 Nonstatutory Stock Options with fifty percent (50%) of the Shares vesting on the first anniversary and the remaining fifty percent (50%) vesting agreement on the second anniversary. On August 19, 2016, Signal Bay, Inc. (the Company) entered into an 8% convertible promissory note (the "Note") with LG Capital Funding, LLC. ("Lender") in the amount of $76,650. Of this amount $3,650 was an original issue discount (OID) and $3,000 was expensed on legal fees. The company received $70,000 and it was funded on August 22, 2016 (Purchase Date). Lender has the right at any time after six months, at its election, to convert (each instance of conversion is referred to herein as a Conversion) all or any part of the Outstanding Balance into shares (Conversion Shares) of fully paid and non-assessable common stock, $0.0001 par value per share (Common Stock), of Borrower as per the following conversion formula: the number of Conversion Shares equals the amount being converted (the Conversion Amount) divided by the Conversion Price. The conversion shall be equal to (a) 55% of the lowest trading price of the Company's common stock during the 20 consecutive trading days prior to the date on which Holder elects to convert all or part of the Note. On September 1, 2016, we issued 193,750 shares that vested to members of our advisory committee under the Companys 2015 Equity Incentive Plan, that were valued at $1,608. |
SUMMARY OF SIGNIFICANT ACCOUN17
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Jun. 30, 2016 | |
Summary Of Significant Accounting Policies Policies | |
Basis of Presentation | The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Companys most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited consolidated financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. |
Principles of Consolidation | The Company prepares its financial statements on the accrual basis of accounting. The accompanying consolidated financial statements include the accounts of the Company and its wholly and partially owned subsidiaries, all of which have a fiscal year end of September 30. All significant intercompany accounts, balances and transactions have been eliminated in the consolidation. The Company consolidates its subsidiaries in accordance with ASC 810, and specifically ASC 810-10-15-8 which states, the usual condition for a controlling financial interest is ownership of a majority voting interest, and, therefore, as a general rule ownership by one reporting entity, directly or indirectly, or over 50% of the outstanding voting shares of another entity is a condition pointing toward consolidation. |
Use of Estimates | The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements estimates or assumptions could have a material impact on Signal Bay, Inc. financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Signal Bay, Inc. financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented. |
Financial Instruments | Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company's financial instruments consist principally of cash, accounts payable, and accrued liabilities. Pursuant to ASC 820 and 825, the fair value of cash is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. The following table sets forth by level with the fair value hierarchy the Company's financial assets and liabilities measured at fair value on June 30, 2016: Level 1 Level 2 Level 3 Total Liabilities Derivative financial instruments $ - $ - $ 376,710 $ 376,710 |
Recently Issued Accounting Pronouncements | Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company. |
SUMMARY OF SIGNIFICANT ACCOUN18
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 9 Months Ended |
Jun. 30, 2016 | |
Summary Of Significant Accounting Policies Tables | |
Financial Instruments | The following table sets forth by level with the fair value hierarchy the Company's financial assets and liabilities measured at fair value on June 30, 2016: Level 1 Level 2 Level 3 Total Liabilities Derivative financial instruments $ - $ - $ 376,710 $ 376,710 |
ACQUISITIONS (Tables)
ACQUISITIONS (Tables) | 9 Months Ended |
Jun. 30, 2016 | |
Summary of the Company's operations with CR Labs, Inc. | In accordance with ASC 805-10-50, the Company is providing the following unaudited pro-forma to present a summary of the combined results of the Companys consolidated operations with all acquisitions. as if the acquisitions had been completed as of the beginning of the reporting period. Adjustments were made to eliminate any inter-company transactions in the periods presented. SIGNAL BAY, INC. AND SUBSIDIARIES STATEMENTS OF CONSOLIDATED OPERATIONS (Unaudited) Nine months ended June 30, 2016 June 30, 2015 (Pro Forma) (Pro Forma) Revenues Testing Services $ 470,504 $ 253,948 Consulting Services 228,612 16,812 Total Revenue 699,116 270,760 Selling, general and administrative expenses 1,048,722 1,195,942 Depreciation and Amortization 72,717 106,951 Operating Expenses 1,121,439 1,302,893 Loss from Operations (422,323 ) (1,032,133 ) Other expense Other (income) expense - (11,036 ) Interest expense 185,363 185,372 Loss on disposal of assets 720 720 Loss on derivatives 238,038 238,038 Other (income) expense 424,121 413,094 Net Loss $ (846,444 ) $ (1,445,227 ) |
Schedule of future amortization associated with the intangible assets acquired | The future amortization associated with the intangible assets acquired in the above mentioned acquisitions is as follows: For the years ended September 30, Amortization 2017 $ 239,401 2018 239,401 2019 239,401 2020 239,401 2021 146,232 Thereafter - Total $ 1,103,836 |
CR Labs, Inc. [Member] | |
Fair values of the assets acquired and liabilities | The following table shows the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: ASSETS ACQUIRED: CASH $ 2,970 ACCOUNT RECEIVABLE 3,550 PROPERTY PLANT AND EQUIPMENT 43,360 CUSTOMER LIST 67,428 GOODWILL 446,743 TOTAL ASSETS ACQUIRED 564,051 LESS LIABILITIES ASSUMED ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (36,421 ) NOTES PAYABLE (27,630 ) TOTAL LIABILITIES ASSUMED (64,051 ) LESS NONCONTROLLING INTEREST (100,000 ) NET ASSETS ACQUIRED FROM CR LABS ACQUISITION $ 400,000 |
Oregon Analytical Services, LLC [Member] | |
Fair values of the assets acquired and liabilities | The following table shows the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Oregon Analytical Services PPA ASSETS ACQUIRED: PROPERTY PLANT AND EQUIPMENT $ 123,143 CUSTOMER LIST 696,153 GOODWILL 60,704 TOTAL ASSETS ACQUIRED 880,000 LESS LIABILITIES ASSUMED NOTES PAYABLE (27,500 ) TOTAL LIABILITIES ASSUMED (27,500 ) NET ASSETS ACQUIRED FROM OREGON ANALYTICAL SERVICES $ 852,500 |
Smith Scientific Industries, Inc. [Member] | |
Fair values of the assets acquired and liabilities | The following table shows the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Smith Scientific Industries ("SSI") PPA ASSETS ACQUIRED: CASH $ 9,055 PROPERTY PLANT AND EQUIPMENT 11,076 CUSTOMER LIST 433,425 GOODWILL 151,824 TOTAL ASSETS ACQUIRED 605,380 LESS LIABILITIES ASSUMED ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (430 ) NOTES PAYABLE (16,200 ) TOTAL LIABILITIES ASSUMED (16,630 ) LESS NONCONTROLLING INTEREST (117,750 ) NET ASSETS ACQUIRED FROM SSI ACQUISITION $ 471,000 |
LOANS PAYABLE (Tables)
LOANS PAYABLE (Tables) | 9 Months Ended |
Jun. 30, 2016 | |
Loans Payable Tables | |
Schedule of loans payable outstanding | The Company had the following loans payable outstanding as of June 30, 2016 and September 30, 2015: June 30, 2016 September 30, 2015 On April 20, 2016, the Company entered into a Purchase and Sale of Future Receivables agreement (the Agreement) with 1 Global Capital, LLC (1GC) for $40,000. The Agreement calls for 140 daily payments of $400, due on business days, for total payments of $56,000. The Company recognized an original debt discount of $16,000 as interest expense. $ 36,800 $ - On May 24, 2016, the Company assumed a $27,500 Promissory note with annual interest of 25%, as part of the acquisition of Oregon Analytical Services (see note 3). The note is due on demand and requires quarterly payments. 27,500 - 64,300 - Less: current portion of loans payable 64,300 - Long-term portion of loans payable $ - $ - |
CONVERTIBLE DEBT (Tables)
CONVERTIBLE DEBT (Tables) | 9 Months Ended |
Jun. 30, 2016 | |
Convertible Debt Tables | |
Schedule of convertible notes payable outstanding | The Company had the following convertible notes payable outstanding as of June 30, 2016 and September 30, 2015: June 30, 2016 September 30, 2015 St. George Investments, LLC. $ - $ 102,500 Adar Bays, LLC 25,000 - Tangiers Global, LLC - note 1 72,020 - Tangiers Global, LLC note 2 27,500 - Tangiers Global, LLC note 3 76,650 - LG Capital Funding, LLC 76,650 - T McNeil Advisors, LLC 45,000 - Total convertible notes payable 322,820 102,500 Less: debt discount and financing fees (109,571 ) (64,062 ) 213,249 38,438 Less: current portion of convertible notes payable 213,249 38,438 Long-term portion of convertible notes payable $ - $ - |
DERIVATIVE LIABILITY (Tables)
DERIVATIVE LIABILITY (Tables) | 9 Months Ended |
Jun. 30, 2016 | |
Derivative Liability Tables | |
Fair value of the derivative using a Black-Scholes option-pricing model | The following table summarizes the derivative liability activity from September 30, 2015 through June 30, 2016. Derivative liabilities Balance - September 30, 2015 $ 200,460 Addition of new derivative 120,000 Day one loss due to derivative 170,637 Loss on change in fair value of the derivative 67,401 Settled upon conversion of debt (181,788 ) Balance - June 30, 2016 $ 376,710 |
Summarizes the derivative liabilities | The following table summarizes the loss on derivative liability included in the income statement for the financial periods ended June 30, 2016 and 2015, respectively. Nine Months Ended June 30, 2016 2015 Day one loss due to derivatives on convertible debt $ 170,637 $ - Loss on change in fair value of the derivative 67,401 - Derivative expense $ 238,038 $ - |
Summarizes the loss on derivative liability | The table below shows the Black-Scholes option-pricing model inputs used by the Company to value the derivative liability, as well as the determined value of the option liability at each measurement date: 6/30/2016 Assumptions Convertible Debt Dividend yield 0.00 % Market price $ 0.0007 Risk-free rate for term 0.21% - 0.59 % Volatility 251.92% - 323.98 % Remaining life (in years) 0.24 - 1.00 |
INDUSTRY SEGMENTS (Tables)
INDUSTRY SEGMENTS (Tables) | 9 Months Ended |
Jun. 30, 2016 | |
Industry Segments Tables | |
Resale to patients and consumer | Nine Months Ended June 30, 2016 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 228,612 $ 163,366 $ 391,978 Segment loss from operations (173,229 ) (112,917 ) (120,692 ) (406,838 ) Total assets 18,545 116,504 2,036,821 2,171,870 Capital expenditures - - 12,407 12,407 Depreciation and amortization - 17,766 53,375 71,141 Nine Months Ended June 30, 2015 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 16,812 $ - $ 16,812 Segment loss from operations (338,509 ) (781,785 ) - (1,120,294 ) Total assets 4,345 139,910 - 144,255 Capital expenditures - 5,694 - 5,694 Depreciation - 10,680 - 10,680 Three Months Ended June 30, 2016 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 32,939 $ 83,709 $ 116,648 Segment income (loss) from operations (34,716 ) (78,980 ) (59,075 ) (172,771 ) Total assets 18,545 116,504 2,036,821 2,171,870 Capital expenditures - - 726 726 Depreciation - (820 ) 47,801 46,981 Three Months Ended June 30, 2015 Corporate Consulting Services Testing Services Total Consolidated Revenue $ - $ 6,399 $ - $ 6,399 Segment loss from operations (22,681 ) (297,471 ) - (320,152 ) Total assets 4,345 139,910 - 144,255 Capital expenditures - 5,694 - 5,694 Depreciation - 5,612 - 5,612 |
SUMMARY OF SIGNIFICANT ACCOUN24
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | Jun. 30, 2016 | Sep. 30, 2015 |
Liabilities | ||
Derivative financial instruments | $ 376,710 | $ 200,460 |
Fair Value, Inputs, Level 1 [Member] | ||
Liabilities | ||
Derivative financial instruments | ||
Fair Value, Inputs, Level 2 [Member] | ||
Liabilities | ||
Derivative financial instruments | ||
Fair Value, Inputs, Level 3 [Member] | ||
Liabilities | ||
Derivative financial instruments | $ 376,710 |
ACQUISITIONS (Details)
ACQUISITIONS (Details) - USD ($) | Jun. 30, 2016 | Sep. 30, 2015 |
ASSETS ACQUIRED: | ||
GOODWILL | $ 659,271 | $ 446,743 |
CR Labs, Inc. [Member] | ||
ASSETS ACQUIRED: | ||
CASH | 2,970 | |
ACCOUNT RECEIVABLE | 3,550 | |
PROPERTY PLANT AND EQUIPMENT | 43,360 | |
CUSTOMER LIST | 67,428 | |
GOODWILL | 446,743 | |
TOTAL ASSETS ACQUIRED | 564,051 | |
LESS LIABILITIES ASSUMED | ||
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES | (36,421) | |
NOTES PAYABLE | (27,630) | |
TOTAL LIABILITIES ASSUMED | (64,051) | |
LESS NONCONTROLLING INTEREST | (100,000) | |
NET ASSETS ACQUIRED FROM CR LABS ACQUISITION | 400,000 | |
Oregon Analytical Services, LLC [Member] | ||
ASSETS ACQUIRED: | ||
PROPERTY PLANT AND EQUIPMENT | 123,143 | |
CUSTOMER LIST | 696,153 | |
GOODWILL | 60,704 | |
TOTAL ASSETS ACQUIRED | 880,000 | |
LESS LIABILITIES ASSUMED | ||
NOTES PAYABLE | (27,500) | |
TOTAL LIABILITIES ASSUMED | (27,500) | |
NET ASSETS ACQUIRED FROM CR LABS ACQUISITION | 852,500 | |
Smith Scientific Industries, Inc. [Member] | ||
ASSETS ACQUIRED: | ||
CASH | 9,055 | |
PROPERTY PLANT AND EQUIPMENT | 11,076 | |
CUSTOMER LIST | 433,425 | |
GOODWILL | 151,824 | |
TOTAL ASSETS ACQUIRED | 605,380 | |
LESS LIABILITIES ASSUMED | ||
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES | (430) | |
NOTES PAYABLE | (16,200) | |
TOTAL LIABILITIES ASSUMED | (16,630) | |
LESS NONCONTROLLING INTEREST | (117,750) | |
NET ASSETS ACQUIRED FROM CR LABS ACQUISITION | $ 471,000 |
ACQUISITIONS (Details 1)
ACQUISITIONS (Details 1) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Revenues | ||||
Testing services | $ 83,709 | $ 163,366 | ||
Consulting services | 32,939 | 6,399 | 228,612 | 16,812 |
Total Revenue | 116,648 | 6,399 | 391,978 | 16,812 |
Operating expenses | ||||
Selling, general and administrative expenses | 242,438 | 320,939 | 727,675 | 1,126,426 |
Depreciation and amortization | 46,981 | 5,612 | 71,142 | 10,680 |
Operating Expenses | 289,419 | 326,551 | 798,816 | 1,137,106 |
Other expense | ||||
Interest expense | 44,397 | 185,372 | ||
Loss on disposal of assets | (720) | |||
Loss on derivatives | (203,696) | (238,038) | ||
Net Loss | $ (420,864) | $ (320,152) | (830,968) | (1,120,294) |
Acquisitions [Member] | ||||
Revenues | ||||
Testing services | 470,504 | 253,948 | ||
Consulting services | 228,612 | 16,812 | ||
Total Revenue | 699,116 | 270,760 | ||
Operating expenses | ||||
Selling, general and administrative expenses | 1,048,722 | 1,195,942 | ||
Depreciation and amortization | 72,717 | 106,951 | ||
Operating Expenses | 1,121,439 | 1,302,893 | ||
Loss from Operations | (422,323) | (1,032,133) | ||
Other expense | ||||
Other (income) expense | (11,036) | |||
Interest expense | 185,363 | 185,372 | ||
Loss on disposal of assets | 720 | 720 | ||
Loss on derivatives | 238,038 | 238,038 | ||
Other (income) expense | 424,121 | 413,094 | ||
Net Loss | $ (846,444) | $ (1,445,227) |
ACQUISITIONS (Details 2)
ACQUISITIONS (Details 2) | Jun. 30, 2016USD ($) |
Acquisitions Details 2 | |
2,017 | $ 239,401 |
2,018 | 239,401 |
2,019 | 239,401 |
2,020 | 239,401 |
2,021 | 146,232 |
Thereafter | |
Total | $ 1,103,836 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 9 Months Ended | |
Jun. 30, 2016 | Sep. 30, 2015 | |
Current Portion - Notes Payable - Related Party | $ 343,007 | $ 133,507 |
Notes Payable - Related Party, less Current Portion | 880,085 | 13,047 |
Lori Glauser [Member] | ||
Borrowed amount | 20,500 | |
Company repaid | 8,795 | |
Total amount owed | 91,705 | 80,000 |
Newport Commercials Advisors [Member] | ||
Consulting fees | $ 48,006 | |
Percentage owned by CEO of Signal Bay, Inc. | 100.00% | |
Libra Wellness Center, LLC [Member] | ||
Total amount owed | $ 40,000 | 40,000 |
Eric Ezrine, CR Labs, President [Member] | ||
Company repaid | 9,951 | |
Total amount owed | 16,603 | 26,554 |
Current Portion - Notes Payable - Related Party | 14,043 | 13,047 |
Notes Payable - Related Party, less Current Portion | 2,560 | 13,507 |
Sara Lausmann [Member] | ||
Company repaid | 24,916 | |
Total amount owed | 747,584 | 0 |
Current Portion - Notes Payable - Related Party | 47,584 | |
Notes Payable - Related Party, less Current Portion | 700,000 | |
Anthony Smith [Member] | ||
Company repaid | 25,000 | |
Total amount owed | 311,000 | 0 |
Current Portion - Notes Payable - Related Party | 133,475 | |
Notes Payable - Related Party, less Current Portion | 177,525 | |
Anthony Smith One [Member] | ||
Borrowed amount | 16,200 | |
Company repaid | 0 | |
Total amount owed | $ 16,200 | $ 0 |
EQUITY TRANSACTIONS (Details Na
EQUITY TRANSACTIONS (Details Narrative) - USD ($) | 9 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Sep. 30, 2015 | |
Series A Convertible Preferred Stock, Shares Issued | 1,840,000 | 1,840,000 | |
Series A Convertible Preferred Stock, Shares Outstanding | 1,840,000 | 1,840,000 | |
Series B Convertible Preferred Stock, Shares Issued | 5,000,000 | 5,000,000 | |
Series B Convertible Preferred Stock, Shares Outstanding | 5,000,000 | 5,000,000 | |
Series C Convertible Preferred Stock, Shares Issued | 500,000 | 0 | |
Series C Convertible Preferred Stock, Shares Outstanding | 500,000 | 0 | |
Common shares issued for equity incentive plan, Amount | $ 38,141 | ||
Common shares issued for equity incentive plan, Shares | 5,506,250 | ||
Common shares issued for consulting services, Amount | $ 54,850 | ||
Common shares issued for consulting services, Shares | 18,585,469 | ||
Conversion of Convertible note and accrued interest into common stock, Shares | 162,246,500 | ||
Conversion of Convertible note and accrued interest into common stock, Amount | $ 88,357 | ||
Reclassification of derivative liability to APIC | $ 181,788 | ||
Common stock, shares issued | 584,986,814 | 398,648,595 | |
Common stock, shares outstanding | 584,986,814 | 398,648,595 | |
Smith Scientific Industries, Inc. [Member] | |||
Series C Convertible Preferred Stock, Shares Issued | 300,000 | ||
Oregon Analytical Services, LLC [Member] | |||
Series C Convertible Preferred Stock, Shares Issued | 200,000 |
LOANS PAYABLE (Details)
LOANS PAYABLE (Details) - USD ($) | Jun. 30, 2016 | Sep. 30, 2015 |
Loan Payable | $ 64,300 | |
Less: current portion of loans payable | 64,300 | |
Long-term portion of loans payable | ||
Loans Payable [Member] | ||
Loan Payable | 36,800 | |
Loans Payable One [Member] | ||
Loan Payable | $ 27,500 |
LOANS PAYABLE (Details Narrativ
LOANS PAYABLE (Details Narrative) - USD ($) | 9 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Sep. 30, 2015 | |
Loans Payable Details Narrative | |||
Accrued interest | $ 697 | $ 0 | |
Interest expense | $ 16,697 | $ 0 |
CONVERTIBLE DEBT (Details)
CONVERTIBLE DEBT (Details) - USD ($) | Jun. 30, 2016 | Sep. 30, 2015 |
Total convertible notes payable | $ 322,820 | $ 102,500 |
Less: debt discount and financing fees | (109,571) | (64,062) |
Convertible Loan | 213,249 | 38,438 |
Less: current portion of convertible notes payable | 213,249 | 38,438 |
Long-term portion of convertible notes payable | ||
St. George Investments, LLC [Member] | ||
Total convertible notes payable | 102,500 | |
Adar Bays, LLC [Member] | ||
Total convertible notes payable | 25,000 | |
Tangiers Global, LLC Note 1 [Member] | ||
Total convertible notes payable | 72,020 | |
Tangiers Global, LLC Note 2 [Member] | ||
Total convertible notes payable | 27,500 | |
Tangiers Global, LLC Note 3 [Member] | ||
Total convertible notes payable | 76,650 | |
LG Capital Funding, LLC [Member] | ||
Total convertible notes payable | 76,650 | |
T McNeil Advisors, LLC [Member] | ||
Total convertible notes payable | $ 45,000 |
CONVERTIBLE DEBT (Details Narra
CONVERTIBLE DEBT (Details Narrative) - USD ($) | 9 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Sep. 30, 2015 | |
Convertible Debt Details Narrative | |||
Amortization of debt discount | $ 90,291 | ||
Convertible debt principal amount | 85,348 | ||
Convertible Interest | 3,008 | ||
Debt Issued | 250,800 | ||
Derivative Liabiity | 376,710 | $ 200,460 | |
Day one loss due to derivative | 170,637 | ||
Debt discount | $ 235,019 | ||
Conversion of Convertible note and accrued interest into common stock, Shares | 162,246,500 |
DERIVATIVE LIABILITY (Details)
DERIVATIVE LIABILITY (Details) - USD ($) | 9 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
Derivative liabilities September 30, 2015 | $ 200,460 | |
Day one loss due to derivative | 170,637 | |
Balance - June 30, 2016 | 376,710 | |
Derivative Liability [Member] | ||
Derivative liabilities September 30, 2015 | 200,460 | |
Addition of new derivative | 120,000 | |
Day one loss due to derivative | 170,637 | |
Loss on change in fair value of the derivative | 67,401 | |
Settled upon conversion of debt | (181,788) | |
Balance - June 30, 2016 | $ 376,710 |
DERIVATIVE LIABILITY (Details 1
DERIVATIVE LIABILITY (Details 1) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Day one loss due to derivatives on convertible debt | $ 170,637 | |||
Derivative expense | $ (203,696) | (238,038) | ||
Derivative Liability [Member] | ||||
Day one loss due to derivatives on convertible debt | 170,637 | |||
Loss on change in fair value of the derivative | 67,401 | |||
Derivative expense | $ 238,038 |
DERIVATIVE LIABILITY (Details 2
DERIVATIVE LIABILITY (Details 2) - Convertible Debt [Member] | 9 Months Ended |
Jun. 30, 2016$ / shares | |
Dividend yield | 0.00% |
Market price | $ 0.0007 |
Minimum [Member] | |
Risk-free rate for term | 0.21% |
Volatility | 251.92% |
Remaining life | 2 months 27 days |
Maximum [Member] | |
Risk-free rate for term | 0.59% |
Volatility | 323.98% |
Remaining life | 1 year |
INDUSTRY SEGMENTS (Details)
INDUSTRY SEGMENTS (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Revenue | $ 116,648 | $ 6,399 | $ 391,978 | $ 16,812 |
Corporate [Member] | ||||
Revenue | ||||
Segment loss from operations | (34,716) | (22,681) | (173,229) | (338,509) |
Total assets | 18,545 | 4,345 | 18,545 | 4,345 |
Capital expenditures | ||||
Depreciation and amortization | ||||
Consulting Services [Member] | ||||
Revenue | 32,939 | 6,399 | 228,612 | 16,812 |
Segment loss from operations | (78,980) | (297,471) | (112,917) | (781,785) |
Total assets | 116,504 | 139,910 | 116,504 | 139,910 |
Capital expenditures | 5,694 | 5,694 | ||
Depreciation and amortization | (820) | 5,612 | 17,766 | 10,680 |
Testing Services [Member] | ||||
Revenue | 83,709 | 163,366 | ||
Segment loss from operations | (59,075) | (120,692) | ||
Total assets | 2,036,821 | 2,036,821 | ||
Capital expenditures | 726 | 12,407 | ||
Depreciation and amortization | 47,801 | 53,375 | ||
Total Consolidated [Member] | ||||
Revenue | 116,648 | 6,399 | 391,978 | 16,812 |
Segment loss from operations | (172,771) | (320,152) | (406,838) | (1,120,294) |
Total assets | 2,171,870 | 144,255 | 2,171,870 | 144,255 |
Capital expenditures | 726 | 5,694 | 12,407 | 5,694 |
Depreciation and amortization | $ 46,981 | $ 5,612 | $ 71,141 | $ 10,680 |